ABVC
ABVC BioPharma, Inc. Common Stock
Latest price
As of Oct 26, 2026, 4:00 PM EDT · Market data by Massive
Market cap
$27.8M
Volume
36.6K
Previous close
$1.04
Day range
$1.03 – $1.07
Listed
Nov 9, 2004
Coverage
35 articles
Price performance
Recent trading
Newsroom
Latest ABVC coverage
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
[ad_1] FREMONT, CA – (NewMediaWire) – February 15, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to license certain of its healthcare-related expert
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
[ad_1] FREMONT, CA – (NewMediaWire) – February 8, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
[ad_1] FREMONT, CA – (NewMediaWire) – January 3, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary r
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
[ad_1] FREMONT, CA – (NewMediaWire) – December 07, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase II part II clinical study taking place a
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
[ad_1] FREMONT, CA – (NewMediaWire) – December 05, 2023 – ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today shared an interview with Dr. Scott Irwin, MD, Ph.D., an eminent Professor of Psychiatry an
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
[ad_1] FREMONT, CA – (NewMediaWire) – November 21, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a U.S. patent, Application No. 17/120,965, for the use of PDC-1421, a Ra
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
[ad_1] FREMONT, CA – (NewMediaWire) – November 16, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with Ai
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
[ad_1] FREMONT, CA – (NewMediaWire) – November 15, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023. These resul
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
[ad_1] FREMONT, CA – (NewMediaWire) – October 26, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet regarding a multi-yea
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
[ad_1] FREMONT, CA – (NewMediaWire) – October 17, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the Un
ABVC Executes Cooperation Agreement for Strategic Investments
[ad_1] FREMONT, CA – (NewMediaWire) – August 17, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it had entered into a Cooperation Agreement to exchange a 20% own
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
[ad_1] FREMONT, CA – (NewMediaWire) – August 10, 2023 – Fremont, CA – (NewMediaWire) – August 10, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that on August 08, 2023,
ABVC Corporate Update and CEO's Letter to Shareholders
[ad_1] FREMONT, CA – (NewMediaWire) – August 07, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Offi
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
[ad_1] FREMONT, CA – (NewMediaWire) – August 3, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, neurology, and ophthalmology, announced that the Science Park Administration in Taiwan approved the plan for setting up a pilot Good Manufacturin
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
[ad_1] FREMONT, CA – (NewMediaWire) – July 31, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced it has closed on a definitive securities purchase agreement with a single institutional inves
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
[ad_1] The planned partnership aims to establish an integrated platform to facilitate collaborations between researchers and industry leaders. ABVC intends to transfer common shares to Zhonghui at $20 per share in consideration for a twenty percent ownership of Zhonghui's property near Chengdu, China, estimated at $37 million by a third-party valuation compa
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
[ad_1] Fremont, CA – (NewMediaWire) – July 27, 2023 — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced it has entered into a definitive securities purchase agreement with a single institutional in
ABVC BioPharma Announces Reverse Stock Split
[ad_1] FREMONT, CA – (NewMediaWire) – July 24, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced a reverse stock split of its common stock ("Reverse Stock Split") of one post-split share fo
The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency
[ad_1] FREMONT, CA – (NewMediaWire) – July 06, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the visionary new CEO of ABVC has selflessly chosen to forgo a salary, instead opting for sto
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
[ad_1] FREMONT, CA – (NewMediaWire) – June 26, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam) as the new Chief Executive Officer (CEO). Dr. Uttam is
ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand
[ad_1] Fremont, CA – (NewMediaWire) – April 06, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus® Phase II Site Initiation Visit (SIV) at Ramathibodi Hospital, Faculty of Medicine, Mahidol Univ
ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results
[ad_1] Fremont, CA – (NewMediaWire) – March 31, 2023 – ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022. Fu
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
[ad_1] Fremont, CA – (NewMediaWire) – January 05, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology today announced that the US Food & Drug Administration notified the company that the IND application for the proposed clinica
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
[ad_1] FREMONT, CA – (NewMediaWire) – November 14, 2022 – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the third quarter of 2022. These results, including the financial
ABVC BioPharma Selects Additional Vitargus Phase II Study Site
[ad_1] New Australia Site Confirmed to Participate in the Study Fremont, CA – (NewMediaWire) – September 09, 2022 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a new clinical site in Australia has been select
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
[ad_1] Fremont, CA – (NewMediaWire) – July 18, 2022 – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, according to a recent study by Bosson Research, the global Retinal Surgical Instruments market, valued at
Zacks Places Share Value of ABVC BioPharma at $9.50
[ad_1] Fremont, CA – (NewMediaWire) – July 06, 2022 – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Zacks Small-Cap Research report dated June 7, 2022 values ABVC at $9.50 per share based upon a financi
ABVC BioPharma Provides Vitargus Update
[ad_1] Vitargus® Receives Phase II Thailand Central Research Ethics Committee Approval Fremont, CA – (NewMediaWire) – June 30, 2022 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus® Phase II Cl
ABVC BioPharma Submitted Vitargus Phase II Study Plan to Australia HREC
[ad_1] Fremont, CA – (NewMediaWire) – June 16, 2022 – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase II study to the Australian Bellberry Human Research Ethics Committee (HRE
ABVC BioPharma Announces Termination of Two Contracts
[ad_1] Fremont, CA – (NewMediaWire) – June 10, 2022 – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that two contracts entered into in the last 45 days have been terminated. The first of the two contracts, ann
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
[ad_1] Fremont, CA – (NewMediaWire) – June 01, 2022 – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the enrollment progress for the Phase II part 2 clinical study of the Company’s ADHD medicine (ABV-1505). Since
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
[ad_1] Fremont, CA – (NewMediaWire) – May 13, 2022 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has engaged the FreeMind Group to help ABVC explore and identify funding opportunities from non-dilutive sour
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
[ad_1] ABVC BIOPHARMA, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December 31, December 31, 2021 2020 ASSETS Current Assets Cash and cash equivalents $ 5,828,548 $ 4,273,208 ...
ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results
[ad_1] Fremont, CA – (NewMediaWire) – November 15, 2021 – ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes, today announced its financial and operating results for the third quarter of 2021. Third Quarter 2021 Fi
ABVC BioPharma Reports Second Quarter 2021 Results
[ad_1] Clinical Trials Continue Despite COVID-19 Restrictions Fremont, CA – (NewMediaWire) – August 12, 2021 – ABVC Biopharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, today announced its unaudited financial and operating resul